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ABSTRACT
Background Distinguishing genetic variants that cause
disease from variants that are rare but benign is one of
the principal challenges in contemporary clinical
genetics, particularly as variants are identiﬁed at a pace
exceeding the capacity of researchers to characterise
them functionally.
Methods We previously developed a novel method,
called paralogue annotation, which accurately and
speciﬁcally identiﬁes disease-causing missense variants by
transferring disease-causing annotations across families of
related proteins. Here we reﬁne our approach, and apply
it to novel variants found in 2266 patients across two
large cohorts with inherited sudden death syndromes,
namely catecholaminergic polymorphic ventricular
tachycardia (CPVT) or Brugada syndrome (BrS).
Results Over one third of the novel non-synonymous
variants found in these studies, which would otherwise
be reported in a clinical diagnostics setting as ‘variants of
unknown signiﬁcance’, are categorised by our method as
likely disease causing (positive predictive value 98.7%).
This identiﬁed more than 500 new disease loci for BrS
and CPVT.
Conclusions Our methodology is widely transferable
across all human disease genes, with an estimated
150 000 potentially informative annotations in more than
1800 genes. We have developed a web resource that
allows researchers and clinicians to annotate variants
found in individuals with inherited arrhythmias,
comprising a referenced compendium of known missense
variants in these genes together with a user-friendly
implementation of our approach. This tool will facilitate
the interpretation of many novel variants that might
otherwise remain unclassiﬁed.
INTRODUCTION
Inherited arrhythmias such as long QT syndrome
(LQTS), Brugada syndrome (BrS) and catecholami-
nergic polymorphic ventricular tachycardia (CPVT)
are life-threatening diseases, caused predominantly
by genetic variation in ion channels. In BrS,
loss-of-function mutations in the SCN5A-encoded
cardiac sodium channel (MIM 601144) have been
shown to be responsible for 15–30% of cases1 2
with mutations in other minor genes accounting
for a proportion of remaining cases. In CPVT,
gain-of-function mutations in the cardiac ryanodine
receptor encoded by RYR2 (MIM 604772) are
responsible for at least 50% of cases.3
With on-going developments in DNA sequencing
technology, it is expected that clinical genetic
testing will become very widely available. However,
it is increasingly appreciated that many healthy
individuals carry rare variants in disease-associated
genes (3–6% for genes associated with inherited
arrhythmia syndromes),4 5 and that additional
information is required to determine whether a
novel variant identiﬁed during genetic testing is
pathogenic. This is particularly the case for mis-
sense variants (single amino acid substitutions)
caused by single nucleotide variants.
In order to determine whether a rare variant
found in a patient is disease causing, sufﬁciently
powered segregation analysis or functional bio-
chemical characterisation are ideally performed.
However, these are often impractical due to cost
and time constraints, or a lack of phenotypically
characterised family members for segregation
studies. Several in silico algorithms, such as
SIFT and Polyphen6 7 try to predict the effect of
novel variants, based on the conservation and
physicochemical properties of the variant amino
acid, and variants in certain protein regions and
domains have a high probability of pathogenicity.8 9
However, more evidence is needed to classify
variants with sufﬁcient conﬁdence for clinical
application.
We have recently proposed a new method to
analyse novel missense variants and assess their
likelihood of pathogenicity.10 This method, ‘paralo-
gue annotation’, identiﬁes functionally important
residues that are intolerant of variation across fam-
ilies of evolutionarily related proteins (paralogues),
using clinically ascertained human genotype–
phenotype relationships. By aligning the protein
sequences of members of these protein families, we
can identify amino acids that are functionally
equivalent across the different proteins. A variant
that is known to be pathogenic in one member of a
protein family can then be used to annotate the
equivalent amino acid of other members of the
family for which no clinical genetic information
exists (ﬁgure 1). For example, if a missense variant
in RYR1 alters protein function and causes malig-
nant hyperthermia when expressed in skeletal
muscle, then we hypothesise that a novel variant
affecting the equivalent amino acid in RYR2,
expressed in cardiac muscle, is likely to be disease
causing in a patient with CPVT.
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This approach was developed and experimentally validated by
application to a large set of known variants in eight LQTS
genes, and was found to have a positive predictive value (PPV)
of 98.4% in these genes.10 Here we present novel reﬁnements
to increase accuracy, and apply this approach in two large
cohorts of patients with BrS or CPVT to determine whether it
provides additional useful information in a clinical diagnostic
setting. We also report a web application that allows researchers
and clinicians to use paralogue annotation to interrogate novel
variants in arrhythmia genes.
MATERIALS AND METHODS
Identiﬁcation of variants in paralogues of RYR2 and SCN5A
Paralogues of RYR2 and SCN5A, that is, evolutionarily related
genes with homology in sequence and structure, were identiﬁed
using the IUPHAR database on receptor nomenclature11 and
through homology searches (Blastp searches of the SCN5A and
RYR2 protein sequences against the human Refseq protein
database).12 The transcripts and protein isoforms used for
these genes were RYR2: NM_001035/NP_001026 (Refseq),
ENST00000366574/ENSP00000355533 (Ensembl), LRG_402t1/
LRG_402p1 (Locus Reference Genomic) and SCN5A:
NM_198056/NP_932173 (Refseq), ENST00000333535/
ENSP00000328968 (Ensembl), LRG_289t1/LRG_289p1 (Locus
Reference Genomic).
RYR2 has two paralogues, RYR1 and RYR3, which were
included in the sequence alignment. Although RYR3 is not
implicated in human disease it was included to improve the
alignment quality for the protein family. Variants in RYR1 cause
malignant hyperthermia, central core disease, multi-minicore
disease and congenital myopathy. There are 329 RYR1 missense
variants in the Human Gene Mutation Database (HGMD)
affecting 284 distinct amino acid residues.
For SCN5A, 19 paralogues were included: nine voltage-gated
sodium channels, and 10 voltage-gated calcium channels that
show strong sequence and structural homology with the sodium
channels. Fourteen of these 19 paralogues are associated with
Mendelian disease in humans, typically attributable to altered
cellular electrophysiology in the tissue where the paralogue is
expressed, such as epilepsy, myotonia, pain disorders, night
blindness and hemiplegic migraine. SCN5A paralogues and their
disease associations are shown in table 1.
For each paralogue gene, variants reported as pathogenic
were identiﬁed using the HGMD Professional V.2012.3.13 Only
disease-causing missense mutations, that is, single nucleotide
variants causing a single non-terminal amino acid change, were
considered.
Multiple sequence alignment and paralogue annotation
The protein sequences of RYR2 and SCN5A and their respective
paralogues were aligned using the T-Coffee/M-Coffee alignment
packages.14 These packages combine the output of a number of
alignment algorithms into a single consensus alignment and
provide a consensus score at each point in the alignment (0–9),
which is a measure of the reliability of the alignment at each
amino acid residue. Using these alignments, each paralogue
protein residue with a disease-causing variant was mapped onto
the equivalent amino acid residue in RYR2 and SCN5A.
To distinguish aligned amino acids that are truly functionally
equivalent from alignment artefacts, an amino acid alignment
quality classiﬁcation was devised. Mappings were classiﬁed as
high quality if the reference amino acid was conserved between
paralogues, and the alignment consensus score was greater than
3. Medium quality mappings required conservation of the refer-
ence amino acid or a consensus score greater than 3 or more
than one paralogue variant mapping to the same residue. Low
quality mappings did not meet these criteria, and were excluded
from analyses.
Sequencing and paralogue annotation in cohorts with CPVT
and BrS
Sequencing of two large cohorts of unrelated patients with
inherited arrhythmias has previously been reported: all exons of
RYR2 were sequenced in 155 patients with CPVT and 200
healthy controls,4 and all exons of SCN5A were sequenced in
2111 patients with BrS and 1300 healthy controls.5 Paralogue
annotation was applied to novel missense variants identiﬁed in
each cohort. Variants were classiﬁed as ‘novel’ if they had not
Figure 1 An overview of paralogue
annotation. (1) Paralogues
(evolutionarily related genes, with
homologous sequence and protein
domain structures) are identiﬁed for a
gene of interest. A subset of
paralogues for SCN5A is shown here
for illustration. (2) Protein sequences
of paralogues are aligned, identifying
functionally equivalent amino acids
across the protein family. (3)
Disease-causing variants in paralogues
are identiﬁed from previous literature
reports, and their locations are
mapped to the gene of interest.
Variants at these sites have a high
probability of pathogenicity.
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previously been reported at the time of the original report, and
have not subsequently been conﬁrmed in an independent study.
These would conventionally be reported clinically as ‘variants of
unknown signiﬁcance’, pending segregation and/or functional
molecular characterisation.
Mutation status of RYR2 and SCN5A residues
Previous reports of benign and pathogenic variation in RYR2
and SCN5A were collated. HGMD identiﬁed putative disease-
causing variants in both genes. Variants were also extracted
from dbSNP V.137 as part of the Ensembl 69 release.
Population frequency from 1000 Genomes (phase 1) and other
datasets in dbSNP were also used—any variant with more than
one observation and a minor allele frequency (MAF) of greater
than or equal to 0.01 in any population was classiﬁed as benign,
as this is considered incompatible with the population frequen-
cies of BrS and CPVT. In addition, several large published data-
sets of RYR2 and SCN5A pathogenic and benign variants were
assessed.15–20
Residues with one or more missense variants reported as
disease causing were classiﬁed as pathogenic. Residues with
reported benign missense variants or high MAF scores as
described above were classiﬁed benign. Any residue with con-
ﬂicting benign and pathogenic reports (for the same variant or
different variants affecting the same residue), or dbSNP variants
with no population frequency data or MAF of less than 0.01,
were classiﬁed as uncertain. Residues for which no missense var-
iants were known were classiﬁed as unannotated.
Protein domains of RYR2 and SCN5A
Mutation hotspots in RYR2 were deﬁned according to Yano
et al:9 residues 77–466 (N-terminal hotspot), 2246–2534
(central hotspot) and 3778–4959 (channel hotspot). The
SCN5A domains were deﬁned in accordance with the Uniprot
entry Q14524 as used by Kapa et al:8 transmembrane regions
are between residues 127–415, 712–939, 1201–1470 and
1524–1772.
RESULTS
Paralogue annotation is informative in assessing novel
missense variants in clinical cohorts
Variants identiﬁed in two large cohorts of unrelated patients
with inherited arrhythmias were analysed. RYR2 sequencing in
155 CPVT patients identiﬁed 63 distinct variants that were
absent in 200 healthy control references. Of these, 59 were mis-
sense variants, and 31 were not reported in any other previous
or subsequent cases. SCN5A sequencing 2111 BrS patients iden-
tiﬁed 293 distinct SCN5A variants that were absent in 1300
healthy controls. Of these, 193 were missense variants, and 122
were not reported in any other previous or subsequent cases.
Paralogue annotation was applied to these 31 RYR2 and 122
SCN5A variants, which would otherwise be reported clinically
as ‘variants of unknown signiﬁcance’, to determine whether
paralogue mutation annotation is informative and provides
further evidence to reclassify some of these variants as ‘disease
causing’ (ﬁgure 2).
Ten of the 31 novel RYR2 missense variants (32.3%) affected
amino acid residues that were annotated with paralogue muta-
tions, that is, variants in the equivalent residue in RYR1 have
been shown to be disease causing for other human diseases
(table 2). Five of these 10 residues have more than one reported
RYR1 pathogenic mutation. Three of these variants occurred in
the N-terminal hotspot (residues 77–466), ﬁve occurred in the
channel region hotspot (residues 3778–4959) and two occurred
outside the recognised RYR2 mutation hotspots—A549 V and
H2168Q. In addition, ﬁve of the 29 non-novel RYR2 missense
Table 1 SCN5A paralogues
Paralogue
HGMD missense
mutations
HGMD missense
residues
SCN5A
annotations Major diseases
SCN1A 410 327 393 Epilepsy, Dravet syndrome, Hemiplegic migraine
SCN2A 26 26 24 Epilepsy, Neonatal-infantile seizures
SCN3A 1 1 1 Epilepsy
SCN4A 67 53 67 Hyperkalaemic periodic paralysis, myotonia, paramyotoniacongenita, periodic paralysis
SCN7A 0 0 0
SCN8A 1 1 1 Infantile epileptic encephalopathy
SCN9A 53 50 45 Congenital indifference to pain, primary erythermalgia, paroxysmal extreme pain
disorder, Small fibre neuropathy
SCN10A 0 0 0
SCN11A 0 0 0
CACNA1A 63 61 54 Episodic ataxia 2, hemiplegic migraine
CACNA1B 0 0 0
CACNA1C 9 9 4 BrS, LQTS
CACNA1D 1 1 0
CACNA1E 1 1 0
CACNA1F 28 28 27 Night blindness
CACNA1G 2 2 0 Juvenile myoclonic epilepsy
CACNA1H 25 25 13 Epilepsy, autism spectrum disorder
CACNA1I 0 0 0
CACNA1S 13 8 13 Hypokalaemic periodic paralysis, malignant hyperthermia
Nineteen paralogues of SCN5A were used in this study, including voltage-gated sodium channels (SCN-A) and the homologous voltage-gated calcium channels. For each paralogue, the
table shows the total number of distinct missense variants reported in HGMD, the number of distinct amino acid residues affected by these mutations and the number of mutations that
were mapped to equivalent residues in SCN5A. Some of the most prominent diseases associated with these paralogue mutations are also highlighted: these are typically diseases
attributable to abnormalities of membrane excitability in a range of tissues.
BrS, Brugada syndrome; HGMD, Human Gene Mutation Database; LQTS, long QT syndrome.
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variants identiﬁed in the study also had equivalent paralogue
mutations, adding further evidence to the likely pathogenicity of
these variants (see supplementary table S1, available online only).
In SCN5A, 45 of the 122 novel missense variants (36.9%)
were annotated with paralogue mutations (table 3). Fourteen of
these 45 residues have more than one reported paralogue patho-
genic mutation. Forty-one of these variants occurred in the
transmembrane domains of SCN5A, three in the N-terminal
region and one in the interlinker domains. In addition, 26 of
the 70 non-novel SCN5A missense variants identiﬁed in the
study also had equivalent paralogue mutations, adding further
evidence to the likely pathogenicity of these variants (see
supplementary table S2, available online only).
Three variants that are detected in healthy controls in these
two studies are predicted to be pathogenic using our approach,
and are considered false positives for the purpose of this study.
RYR2-M2389 L was identiﬁed in one of 200 controls. This
variant is found in the central domain hotspot of RYR2 and is
not identiﬁed in any of the 1000 Genomes phase 1 samples.
SCN5A-D596G was identiﬁed in one of 1300 controls. Located
in interlinker domain I–II, this variant is also absent in the
phase 1 1000 Genomes data. SCN5A-S216 L has conﬂicting
reports as to its pathogenicity—it has been linked to LQTS,
atrial ﬁbrillation and dilated cardiomyopathy,21–23 but has also
been identiﬁed in healthy controls8 and in low frequencies in
dbSNP populations. Its exact role in causing disease is therefore
still unclear. Although we consider these variants as false posi-
tives here, in the absence of functional data to the contrary, at
least some may be functionally deleterious in controls with non-
penetrant disease or incomplete phenotype data. Importantly,
controls did not undergo any provocation testing (eg, ajmaline
challenge for BrS, and exercise test or adrenaline challenge for
CPVT), which is used to make a diagnosis in some forms of
these diseases and hence latent disease was not excluded.
Table 2 Paralogue annotation of novel variants identified in RYR2
RYR2 variant
CDS Protein Region Cases (n=155) Exon Paralogue Paralogue variant Paralogue disease Consensus
c.527G>A p.R176Q N-terminal hotspot 1 8 RYR1 R163L Malignant hyperthermia 9
RYR1 R163C Central core disease 9
c.994C>T p.R332W N-terminal hotspot 1 12 RYR1 R316L Malignant hyperthermia 8
c.1069G>A p.G357S N-terminal hotspot 1 13 RYR1 G341R Malignant hyperthermia 9
RYR1 G341R Malignant hyperthermia 9
c.1646C>T p.A549V Outside hotspots 1 17 RYR1 A537T Congenital myopathy 9
c.6504C>G p.H2168Q Outside hotspots 2 42 RYR1 H2204Q Multiminicore disease 9
c.7258A>T p.R2420W Central hotspot 1 48 RYR1 R2454C Malignant hyperthermia 9
RYR1 R2454H Malignant hyperthermia 9
c.11989A>G p.K3997E Channel hotspot 1 90 RYR1 R4041W Malignant hyperthermia 9
c.14369G>A p.R4790Q Channel hotspot 1 100 RYR1 R4861C Central core disease 9
RYR1 R4861H Central core disease 9
c.14414A>G p.K4805R Channel hotspot 1 100 RYR1 K4876R Malignant hyperthermia 9
c.14465G>A p.R4822H Channel hotspot 1 101 RYR1 R4893W Central core disease 9
RYR1 R4893Q Central core disease 9
RYR1 R4893P Central core disease 9
Ten out of 31 novel missense variants identified in 155 unrelated CPVT patients10 were annotated. This provides strong evidence of pathogenicity for these variants. In addition, five of
the 29 RYR2 missense variants previously reported to be pathogenic were annotated (see supplementary table S1, available online only).
RYR2 coordinates given with respect to transcripts NM_001035/NP_001026 (Refseq), ENST00000366574/ENSP00000355533 (Ensembl), LRG_402t1/LRG_402p1 (Locus Reference
Genomic).
CDS, coding DNA sequence; CPVT, catecholaminergic polymorphic ventricular tachycardia.
Figure 2 Genetic variation in cohorts with inherited arrhythmia
syndromes. RYR2 or SCN5A were sequenced in 2266 patients with an
inherited arrhythmia syndrome, as shown. Three hundred and
ﬁfty-seven variants were identiﬁed in 511 patients, of which 153 were
novel missense variants. In the absence of segregation or functional
data, these would typically be reported as variants of unknown
signiﬁcance. However, paralogue annotation provided additional
information for 65 (36%) variants, that would further inform a clinical
genetic report. BrS, Brugada syndrome; CPVT, catecholaminergic
polymorphic ventricular tachycardia.
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Table 3 Paralogue annotation of novel variants identified in SCN5A
SCN5A variant
CDS Protein Region Cases (n=2111) Exon Paralogue Paralogue variant Paralogue disease Consensus
c.278T>C p.F93S N-terminus 1 3 SCN1A F90S Myoclonic epilepsy of infancy 5
c.281T>G p.I94S N-terminus 1 3 SCN1A I91T Myoclonic epilepsy of infancy 5
c.362G>A p.R121Q N-terminus 2 3 SCN1A R118S Myoclonic epilepsy of infancy 9
c.533C>G p.A178G TM domain 1 1 5 SCN1A A175V Dravet syndrome 9
SCN1A A175T Myoclonic epilepsy of infancy 9
c.659C>T p.T220I TM domain 1 2 6 SCN1A T217K Myoclonic epilepsy of infancy 9
c.694G>A p.V232I TM domain 1 2 6 CACNA1H R212R Autism spectrum disorder 9
c.1100G>T p.R367L TM domain 1 1 9 SCN1A R377Q Generalised epilepsy with febrile seizures 9
SCN1A R377L Dravet syndrome 9
c.1120T>G p.W374G TM domain 1 1 9 SCN1A W384R Dravet syndrome 9
SCN1A W384X Myoclonic epilepsy of infancy 9
c.1157G>A p.G386E TM domain 1 2 10 SCN1A G396E Dravet syndrome 8
c.1156G>A p.G386R TM domain 1 1 10 SCN1A G396E Dravet syndrome 8
c.1187T>C p.V396A TM domain 1 1 10 SCN1A V406F Dravet syndrome 9
c.1186G>C p.V396L TM domain 1 1 10 SCN1A V406F Dravet syndrome 9
c.2047T>G p.C683G Interdomain Linker I-II 1 14 SCN9A C699Y Dravet syndrome 3
CACNA1H R744Q Childhood absence epilepsy 3
c.2150C>T p.P717L TM Domain 2 1 14 SCN1A P768L Myoclonic epilepsy of infancy 8
c.2553C>A p.F851L TM Domain 2 1 16 SCN1A F902C Myoclonic epilepsy of infancy 9
c.2633G>A p.R878H TM Domain 2 5 16 SCN1A R931C Myoclonic epilepsy of infancy 8
SCN9A R896Q Congenital indifference to pain 8
SCN1A R931H Epilepsy 8
c.2657A>C p.H886P TM Domain 2 1 16 SCN1A H939Q Myoclonic epilepsy of infancy 9
SCN1A H939Y Dravet syndrome 9
CACNA1H W962C Autism spectrum disorder 9
c.2677C>T p.R893C TM Domain 2 2 16 SCN1A R946S Generalised epilepsy of infancy 9
SCN1A R946C Myoclonic epilepsy of infancy 9
SCN1A R946H Myoclonic epilepsy of infancy 9
c.2678G>A p.R893H TM Domain 2 3 16 SCN1A R946S Generalised epilepsy of infancy 9
SCN1A R946C Myoclonic epilepsy of infancy 9
SCN1A R946H Myoclonic epilepsy of infancy 9
c.2701G>A p.E901K TM Domain 2 3 16 SCN1A E954K Dravet syndrome 9
c.3695G>A p.R1232Q TM Domain 3 1 21 SCN1A R1245Q Myoclonic epilepsy of infancy 7
c.3758A>G p.E1253G TM Domain 3 1 21 SCN1A E1266A Dravet syndrome C 9
c.3813G>C p.W1271C TM Domain 3 1 21 SCN1A W1284S Dravet syndrome 9
c.3968T>G p.V1323G TM Domain 3 1 23 SCN9A V1299F Paroxysmal extreme pain disorder 9
c.4057G>A p.V1353M TM Domain 3 2 23 SCN1A V1366I Generalised epilepsy with febrile seizures 9
c.4079T>G p.F1360C TM Domain 3 1 23 CACNA1A F1404C Episodic ataxia 9
c.4226A>G p.Y1409C TM Domain 3 1 23 SCN1A Y1422C Myoclonic epilepsy of infancy 9
c.4234C>T p.L1412F TM Domain 3 1 23 CACNA1F L1079P Night blindness 9
c.4255A>G p.K1419E TM Domain 3 1 24 CACNA1C E1115K BrS 9
c.4258G>C p.G1420R TM Domain 3 1 24 SCN1A G1433R Dravet syndrome 9
SCN1A G1433E Myoclonic epilepsy of infancy 9
SCN1A G1433V Dravet syndrome 9
c.4283C>T p.A1428V TM Domain 3 1 24 SCN1A A1441P Myoclonic epilepsy of infancy 9
c.4321G>C p.E1441Q TM Domain 3 1 25 CACNA1A G1483R Episodic ataxia 9
SCN1A E1454K Dravet syndrome 9
c.4342A>C p.I1448L TM Domain 3 1 25 SCN1A L1461I Myoclonic epilepsy of infancy 9
c.4343T>C p.I1448T TM Domain 3 1 25 SCN1A L1461I Myoclonic epilepsy of infancy 9
c.4346A>G p.Y1449C TM Domain 3 1 25 SCN1A Y1462C Myoclonic epilepsy of infancy 9
CACNA1A F1491S Episodic ataxia 9
SCN1A Y1462H Dravet syndrome 9
c.4387A>T p.N1463Y TM Domain 3 1 25 SCN1A N1476K Dravet syndrome 9
c.4402G>T p.V1468F TM Domain 3 1 25 SCN4A V1293I Paramyotoniacongenita 9
c.4573G>A p.V1525M TM Domain 4 1 27 SCN1A V1538I Dravet syndrome 9
c.4642G>A p.E1548K TM Domain 4 3 27 SCN1A E1561K Dravet syndrome 9
Continued
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Paralogue annotation has previously been validated in eight
LQTS proteins.10 Sites predicted to be disease associated by para-
logue annotation were highly enriched for known disease-causing
variants, with very few false positives. Applying the approach to
RYR2 and SCN5A variants again demonstrates enrichment for
known disease-associated residues (table 4). Two hundred and
seventy-ﬁve RYR2 residues were annotated with paralogue muta-
tions: if distributed at random, eight would be expected to coin-
cide with known pathogenic residues. We observe 35 known
disease-associated residues: a 4.4-fold enrichment. Similarly, 113
disease-associated SCN5A residues are annotated by paralogue
mutations, a 1.4-fold increase over the 81 annotations expected
by random distribution. There is also a signiﬁcant depletion of
known benign residues in SCN5A (expected, six; observed, one).
The positive predictive value (PPV) of paralogue annotation
assessed in the current study is 98.7%, in keeping with previous
ﬁndings in LQTS genes (98.4% PPV).10 By comparison, of 519
known missense variants in RYR2 and SCN5A predicted by SIFT
to be deleterious, 500 are correct (variants with unambiguous
evidence of pathogenicity) with 19 false positives (benign var-
iants), yielding a PPV of 96.5%. Similarly, of 518 variants pre-
dicted to be damaging by Polyphen, 497 are correct with 21 false
positives, with a PPVof 95.9%.
Importantly, the paralogue approach is informative for a large
number of residues at which no variation has previously been
reported, when variation detected in clinical testing would
otherwise be reported as a ‘variant of unknown signiﬁcance’.
Paralogue annotation is informative for 238 unannotated RYR2
residues and 321 unannotated SCN5A residues, and was inform-
ative for more than one-third of novel variants identiﬁed in
these large clinical cohorts. It is expected that any missense var-
iants identiﬁed in these residues in CPVT or BrS patients are
likely to be disease causing.
Distribution of variation across protein domains
Protein regions that are known to be enriched for pathogenic
variation were also enriched in paralogue annotations (com-
pared with expectation under a random distribution; table 5).
One hundred and seventy-two of the 275 paralogue mutations
mapped to RYR2 occur in the three mutations hotspots, an
enrichment factor of 1.52. Similarly, 227 of the 441 paralogue
mutations mapped to SCN5A occur in the four transmembrane
domains, an enrichment factor of 1.57. As might be expected,
disease-causing variants display similar domain distributions
across the protein families: RYR1 has similar overlapping muta-
tion hotspots to RYR2 (ﬁgure 3) and 75.8% of the missense
mutations in the voltage-gated sodium and calcium channel
paralogues of SCN5A occur in their transmembrane domains,
despite these regions only accounting for 50.5% of the protein
length.
Reciprocal paralogue annotation: RYR1
This technique is also applicable in a reciprocal fashion, that is,
arrhythmia-causing mutations in RYR2 and SCN5A can be used
to interpret novel variants found in any of the paralogues ana-
lysed in this study. As an example, we have mapped all the
mutations in RYR2 that cause CPVT and other cardiac diseases
onto RYR1, which can be used to assess novel missense variants
found in patients with malignant hyperthermia or central core
disease.
As expected, residues predicted to be intolerant of variation
by paralogue annotation are indeed highly enriched for known
disease-associated variants in RYR1 (4.4-fold enrichment;
observed, 35; expected, eight). None of the four RYR1 residues
that host missense variants with a MAF greater than 0.01 in
1000 Genomes (that are therefore presumably benign) were
annotated, giving a notional PPV of 100%. In addition, 99 pre-
viously unannotated RYR1 residues are predicted to be intoler-
ant of variation, of which 22 lie outside the traditional RYR1
mutation hotspots.
Web-based paralogue annotation application
We have developed a web-based tool to allow researchers and
clinicians to identify paralogue annotations for novel variants to
inform pathogenicity. This is available for RYR2 and SCN5A, as
well as other LQTS-associated genes previously reported. Users
input the coordinates of a novel variant (protein or complemen-
tary DNA coordinates) in a gene of interest, and any paralogue
mutations associated with that residue are returned, together
with fully referenced details of any known (pathogenic or
benign) missense variants in the query gene. The quality of the
mapping is crucial when using paralogue annotation to predict
Table 3 Continued
SCN5A variant
CDS Protein Region Cases (n=2111) Exon Paralogue Paralogue variant Paralogue disease Consensus
c.4747C>T p.R1583C TM Domain 4 2 27 SCN1A R1596C Cryptogenic focal epilepsy 9
SCN1A R1596L Dravet syndrome 9
SCN1A R1596H Generalised epilepsy with febrile seizures 9
c.4748G>A p.R1583H TM Domain 4 1 27 SCN1A R1596C Cryptogenic focal epilepsy 9
SCN1A R1596L Dravet syndrome 9
SCN1A R1596H Generalised epilepsy with febrile seizures 9
c.4981G>C p.G1661R TM Domain 4 1 28 SCN1A G1674R Myoclonic epilepsy of infancy 9
c.4981G>A p.G1661R TM Domain 4 2 28 SCN1A G1674R Myoclonic epilepsy of infancy 9
c.5015C>A p.S1672Y TM Domain 4 2 28 SCN1A A1685D Myoclonic epilepsy of infancy 9
SCN1A A1685V Febrile seizures 9
c.5134G>A p.G1712S TM Domain 4 1 28 SCN1A G1725C Dravet syndrome 9
Forty-five out of 122 novel missense variants identified in 2111 unrelated BrS patients5 were annotated. In addition, 26 of the 70 SCN5A missense variants previously reported to be
pathogenic were annotated (see supplementary table S2, available online only).
SCN5A coordinates given with respect to transcripts NM_198056/NP_932173 (Refseq), ENST00000333535/ENSP00000328968 (Ensembl), LRG_289t1/LRG_289p1 (Locus Reference
Genomic).
BrS, Brugada syndrome; CDS, coding DNA sequence; TM, transmembrane.
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pathogenicity. The web interface will assign each mapping a high,
medium or low quality rating (deﬁned using the alignment con-
sensus, reference amino acids in the query and paralogue proteins
and number of mappings as described in the Methods section
above). In addition, the segment of the multiple sequence align-
ment around the mapping is displayed to allow users to assess the
degree of homology visually between the proteins at that residue,
coloured by the consensus between the different alignment algo-
rithms used by the M-Coffee and T-Coffee packages. Finally,
links to the publications describing the pathogenic paralogue
mutations are available, allowing users to assess how well the
mutation has been characterised in the paralogue-associated
disease. The application is shown in ﬁgure 4.
DISCUSSION
In this study we have shown that over one-third (36%) of novel
missense variants identiﬁed in large cohorts of patients with
CPVT (RYR2) and BrS (SCN5A) can be annotated by paralogue
mutations. This additional evidence of pathogenicity may allow
us to reclassify as disease causing up to one-third of variants cur-
rently reported as ‘variants of unknown signiﬁcance’, with a
positive PPV exceeding 98%.10 There is a bias towards reporting
pathogenic variants over benign variants in the literature, and
although we have supplemented literature reports with data
from 1000 Genomes and the Exome Sequencing Project, it is
possible that these PPV values may be overestimated. However,
as these data derive from clinically observed genotype–pheno-
type relationships within closely related protein families, rather
than theoretical predictions based on the sequence and structure
of much more distantly related proteins, we have conﬁdence in
this approach and these annotations.
In a clinical setting, the identiﬁcation of a novel single amino
acid substitution in a gene associated with inherited disease is
generally insufﬁcient to report the variant as disease causing.
This is due to the relatively high prevalence of rare, benign var-
iants in healthy controls in many genes. Missense variants have
been shown to be present in 6% of controls in RYR24 and in
2.7% of controls in SCN5A.8 Segregation studies and functional
biochemical characterisation are powerful, but resource intensive
and are not always applicable. Computational predictions are
attractive and widely applicable, but while informative they are
not sufﬁciently accurate for robust clinical reporting. It therefore
behoves us to make full use of available reports linking human
variation to clinical phenotype.
When a variant in a disease gene has previously been
observed, either in association with disease or in apparently
healthy individuals, this provides invaluable additional informa-
tion for clinical reporting. However, there is a huge amount of
additional data linking genetic variation to clinical phenotype in
paralogues of disease genes that is not presently used. By
mapping functionally equivalent amino acid residues across
protein families, and transferring genotype–phenotype annota-
tions between related proteins, we can leverage this wealth of
existing data to aid our interpretation of the signiﬁcance of
novel variants in a clinical setting.
The accuracy of this method depends on the quality of the
protein sequence alignment (to ensure that aligned amino acids
can be conﬁdently regarded as functionally equivalent) and the
Table 5 Annotation across protein domains of RYR2 and SCN5A
Known missense variants Paralogue mappings
Gene Protein domains Pathogenic Benign Uncertain Actual Enrichment
SCN5A N-terminus 27 2 6 14 0.51
Transmembrane 277 8 26 355 1.57
Interlinker domains 99 25 35 41 0.31
C-terminus 40 5 16 31 0.58
Total 443 40 83 441
RYR2 Hotspots 134 10 17 157 1.52
Outside hotspots 20 10 59 118 0.69
Total 154 20 76 275
Distribution of known variants and paralogue mutation annotations across protein domains of SCN5A and mutation hotspots of RYR2. There is significant enrichment of both known
pathogenic mutations and paralogue mutation mappings in the protein regions recognised to be susceptible to pathogenic variation, that is, the trans-membrane domains of SCN5A
and the three mutation hotspots of RYR2.
Table 4 Paralogue annotation accurately identifies disease-associated residues in RYR2 and SCN5A
Protein Pathogenic Benign Uncertain Unannotated Total
SCN5A Published observations 368 28 60 1560 2016
Paralogue annotations: observed (expected) 113 (81) 1 (6) 6 (13) 321 (341) 441
RYR2 Published observations 139 20 71 4737 4967
Paralogue annotations: observed (expected) 35 (8) 1 (1) 1 (4) 238 (262) 275
Distribution of paralogue annotations across the amino acid residues of the SCN5A and RYR2 proteins. ‘Published observations’ shows the number of amino acid residues with known
missense variants, classified as pathogenic, benign or uncertain, and the number of residues at which missense variation has not previously been observed (unannotated). ‘Uncertain’
refers to dbSNP variants without clinical information or residues with variants with conflicting reports as to pathogenicity. ‘Paralogue annotations observed’ shows the number of
residues of each class that are annotated by variants in paralogues, and which would therefore be expected to be sites of pathogenic variation. ‘Paralogue annotations expected’ shows
the number of residues in each class that would be expected to be annotated if paralogue annotation was random, with no predictive value. Variants annotated in this way are highly
enriched for pathogenic variation in both genes (2×2 Fisher’s exact test p=0.0009), with a positive predictive value (PPV) of 98.7%. 559 previously unannotated residues (321 in
SCN5A, 238 in RYR2) are identified as putative disease-associated residues.
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quality of the evidence relating genotype to phenotype for the
paralogue variant. For the alignment, appropriate paralogues
should be carefully and manually chosen, while we have
described methods above to ensure that only mappings of sufﬁ-
cient quality are noted. In addition, our web application allows
users to assess the quality of the alignment visually at the
mapping residue. The web application also provides Pubmed
links to allow researchers to assess the quality of the reports
linking the paralogue variants to disease—a functionally charac-
terised variant, or one that has been shown to segregate with
disease, is more informative than a variant simply observed once
in an affected individual. It is critical for researchers to consider
this evidence carefully to avoid inferring pathogenicity from
erroneous reports and also check that the direction of effect of
the variant in the paralogue is compatible with the observed
phenotype in the gene of interest.
The sensitivity of this approach depends on the availability of
known, pathogenic mutations in the paralogues of genes of
interest. The lack of paralogue annotation for a novel variant
does not imply that the variant is non-pathogenic, simply that a
disease-causing mutation in the equivalent paralogue residue has
not yet been observed. As genetic testing becomes more widely
available across the whole spectrum of inherited disease, for
example, through the ongoing development of sequencing
Figure 3 Disease-causing variation in human ryanodine receptors, RYR1 and RYR2. An alignment of RYR1 and RYR2 reveals the structural
similarity of the proteins and homologous clustering of pathogenic variation in these related proteins. The protein is represented in light grey, with
reported ‘mutation hotspots’ marked in dark grey, and exon boundaries highlighted. The locations of missense variants previously reported to be
pathogenic are shown with black lines above and below the protein graphic—longer lines indicate more than one pathogenic DNA variant affecting
the same protein residue.
Figure 4 A web-based application makes paralogue annotation easily accessible for genes causing inherited arrhythmia syndromes. A web-based
application is available at http://cardiodb.org/Paralogue_Annotation/. Users enter the position of a novel variant using complementary DNA or
protein coordinates: in this example a substitution has been found in RYR2, affecting glycine residue 357.1 This residue maps to RYR1 residue 341,
and two cDNA variants at that location (c.1021G>A and c.1021G>C) that each cause substitution of Arg for Gly at that position have been reported
to cause malignant hyperthermia. Users should check the alignment quality—here the mapping quality is high: the surrounding region is highly
homologous, the reference amino acid is the same in both proteins, and the alignment has a high consensus score.2 Pubmed links give access to
the reports relating to the paralogue mutation(s), 3 allowing users to assess the quality of evidence for pathogenicity. Here functional
characterisation has been performed on this variant in the highlighted publication, adding conﬁdence that the variant is disease causing and the
residue is intolerant of variation in both RYR1 and its paralogue RYR2.
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technologies, we expect the number of informative paralogue
mutations to expand greatly, increasing the sensitivity of this
method. Here, an additional 238 residues in RYR2 (a 171%
increase compared with previous reports), and 321 residues in
SCN5A (87% increase) are putatively annotated as intolerant of
variation.
Paralogue annotation is designed to interpret individual var-
iants in monogenic disease and does not currently help to
clarify the genetics of complex multi-alleleic disease. There have
been recent reports linking common genetic variation with pre-
disposition to BrS,24 and there is a debate about the role of
genetic testing in this condition. However as BrS does segregate
as a monogenic Mendelian trait in some pedigrees and most
clinicians still feel that genetic testing of SCN5A is of value,
paralogue annotation can help to interpret these novel variants.
Some regions of RYR2 and SCN5A are enriched for
disease-associated variants, yet contain relatively few benign
polymorphisms, so that variants in these regions have a
higher-than-average previous probability of pathogenicity. While
this is to some extent informative, the accuracy and sensitivity
of a purely domain-based prediction are limited, as many patho-
genic and benign variants do not follow this trend. Paralogue
annotation provides a higher resolution annotation, down to the
level of the individual amino acid. It is also not limited to any
speciﬁc domains or protein regions and is less likely to mis-
annotate a rare benign variant as pathogenic given the high PPV
scores we have seen in this and previous studies.
In RYR2, 134 of the 154 known pathogenic missense muta-
tions occur within the recognised mutation hotspots (ﬁgure 3).
However, 10 known benign missense variants also occur in
these regions, suggesting that novel variants found here cannot
be deﬁnitively classiﬁed as disease causing. In our study we
found that 57% of the paralogue annotations of RYR2 occur in
the mutation hotspots. This is due to the fact that RYR1 contains
equivalent, and largely overlapping, mutation hotspots (ﬁgure
3). Pathogenic mutations in RYR1 are, however, less concen-
trated in these hotspots than in RYR2, which allows us to anno-
tate an additional 114 residues outside conventional RYR2
hotspots. It is likely that this clustering of mutations is at least
partly caused by sequencing bias, that is, often only exons with
known mutations are sequenced in genetic testing. The increas-
ing use of next generation sequencing technologies allows
laboratories to sequence all the exons of ryanodine receptors
and is likely to expand the numbers of mutations found outside
the hotspots of both RYR1 and RYR2 for their respective dis-
eases—paralogue annotation will be able to utilise all of these
ﬁndings to assess variants in either gene.
Pathogenic mutations are not as discreetly clustered in SCN5A
as in RYR2. However, variation in the transmembrane regions is
rare in apparently healthy individuals, and substitutions in these
regions have been reported to have an 88% probability of
pathogenicity when found in clinically affected individuals.8
Here, over 80% of disease-causing variants in SCN5A paralo-
gues map to transmembrane residues, providing further evi-
dence that these domains are functionally important and
intolerant of variation. Most importantly, paralogue annotation
also annotates some variants at residues outside these regions,
whose signiﬁcance would otherwise be unappreciated.
Paralogue annotation of variants is widely applicable:
approximately half of all disease-associated genes have one or
more paralogues with disease-causing variants.10 The technique
can also be applied in a reciprocal manner, as illustrated here
with RYR1 and RYR2, and our web-based application will be
informative for researchers and clinicians interested in a range
of diseases mediated by ion channels and membrane excitability,
such as malignant hyperthermia and central core disease, and as
well as the cardiovascular genetics community.
CONCLUSION
This study demonstrates an accurate and widely applicable
approach to interpret novel missense variants, here applied to
annotate variants in CPVT (RYR2) and BrS (SCN5A). This is
informative for more than one-third of novel variants in these
genes, and may provide sufﬁcient evidence to report these var-
iants as disease causing, rather than as ‘variants of unknown sig-
niﬁcance’, with a positive PPV of 98.7%. This approach is based
on clinical genotype–phenotype relationships in humans, rather
than computational prediction, giving further conﬁdence in its
application. While this method will not be applied in isolation,
due to our incomplete inventory of pathogenic variation in
paralogues, it provides an invaluable additional tool for clini-
cians and researchers. Our web-based application provides a
user-friendly implementation of this technique for immediate
application in the interpretation of novel variants, with an initial
focus on inherited arrhythmia syndrome genes, together with an
annotated compendium of previously reported missense variants
in these genes.
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